Normal view MARC view ISBD view

"Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. [Review]

MedStar author(s):

Citation: JACC Heart Failure. 3(9):661-9, 2015 Sep.PMID: 26362444Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, Non-U.S. Gov't | ReviewSubject headings: *Heart Failure/pp [Physiopathology] | *Myocardial Contraction/ph [Physiology] | *Recovery of Function | *Stroke Volume/ph [Physiology] | *Ventricular Function, Left/ph [Physiology] | Heart Failure/di [Diagnosis] | Humans | Magnetic Resonance Imaging, Cine | Myocardium/pa [Pathology]Year: 2015 ISSN:

2213-1779

Name of journal: JACC. Heart failureAbstract: Myocardial recovery in heart failure (HF) is possible, but its determinants are not fully defined. At least partial functional improvement is possible with current evidence-based therapies. However, once significant HF symptoms develop, patients have varied trajectories, including: 1) structural and functional recovery; 2) stabilization (remission); and 3) acceleration to end-stage HF/death. All 3 trajectories may be interrupted by sudden death. These trajectories may represent the interplay of heterogeneous causality, genetic predeterminants, and disease phenotypes. Enhanced phenotypic description with cardiac magnetic resonance imaging, molecular imaging, or circulating biomarkers of the heterogeneous HF population may provide insights regarding specific biological targets amenable to existing and novel therapeutic strategies. The identification of patients in "remission," before progression to the end stage of predominantly nonviable tissue (e.g., fibrosis), has implications for clinical practice and future trials because such patients may be more likely to experience myocardial recovery (cardiac reserve). The identification of dysfunctional but viable myocardium and its diverse pathophysiological causes may provide opportunities to investigate existing and novel therapeutics aimed at enhancing myocardial recovery.Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.All authors: Ardehali H, Bonow RO, Butler J, Diez J, Epstein SE, Fonarow GC, Gheorghiade M, Khan SS, Kim RJ, Sabbah HN, Sauer AJ, Wilcox JEFiscal year: FY2016Digital Object Identifier:

http://dx.doi.org/10.1016/j.jchf.2015.04.011

Date added to catalog: 2016-07-15

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	26362444	Available		26362444

Myocardial recovery in heart failure (HF) is possible, but its determinants are not fully defined. At least partial functional improvement is possible with current evidence-based therapies. However, once significant HF symptoms develop, patients have varied trajectories, including: 1) structural and functional recovery; 2) stabilization (remission); and 3) acceleration to end-stage HF/death. All 3 trajectories may be interrupted by sudden death. These trajectories may represent the interplay of heterogeneous causality, genetic predeterminants, and disease phenotypes. Enhanced phenotypic description with cardiac magnetic resonance imaging, molecular imaging, or circulating biomarkers of the heterogeneous HF population may provide insights regarding specific biological targets amenable to existing and novel therapeutic strategies. The identification of patients in "remission," before progression to the end stage of predominantly nonviable tissue (e.g., fibrosis), has implications for clinical practice and future trials because such patients may be more likely to experience myocardial recovery (cardiac reserve). The identification of dysfunctional but viable myocardium and its diverse pathophysiological causes may provide opportunities to investigate existing and novel therapeutics aimed at enhancing myocardial recovery.Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

English